The incidence and spectrum of AIDS-defining illnesses in persons treated with antiretroviral drugs

Clinical Infectious Diseases

Volumn 27, Issue 6, 1998, Pages 1379-1385

  Forrest, David M ^b   Seminari, Elena ^b   Hogg, Robert S ^b   Yip, Benita ^b   Raboud, Janet ^b   Lawson, Lindsay ^b   Phillips, Peter ^b   Schechter, Martin T ^b   O'Shaughnessy, Michael V ^b   Montaner, Julio S G ^a  

^a ST PAUL S HOSPITAL   (Canada)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ARTICLE; CANADA; CANDIDIASIS; CYTOMEGALOVIRUS INFECTION; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; KAPOSI SARCOMA; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; PNEUMOCYSTIS PNEUMONIA; PRESCRIPTION; PRIORITY JOURNAL; WASTING SYNDROME;

EID: 0032465676     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/515030     Document Type: Article

References (43)

1. Centers for Disease Control and Prevention. Update: trends in AIDS incidence, deaths, and prevalence - United States, 1996. MMWR Morb Mortal Wkly Rep 1997; 46:165-73.
2. Karon J, Rosenberg P, McQuillan G, Khara M, Gwinn M, Petersen L. Prevalence of HIV infection in the United States, 1984 to 1992. JAMA 1996; 276:126-31.
3. Centers for Disease Control and Prevention. Update: trends in AIDS diagnosis and reporting under the expanded surveillance definition for adolescents and adults - United States, 1993. MMWR Morb Mortal Wkly Rep 1994; 43:826-31.
4. Centers for Disease Control and Prevention. HIV/AIDS surveillance report. Bethesda, Maryland: U.S. Department of Health and Human Services and Public Health Services 1996; 8:3-4, 20, 30-33.
5. Chiasson M, Berenson L, Schwartz S, Mojica B, Hamburg M. Declining AIDS mortality in New York City [abstract no 376]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, VA: IDSA for Foundation for Retroviruses and Human Health, 1997:133.
6. Rutherford G, Schwarcz S, Lemp G, et al. The epidemiology of AIDS-related Kaposi's sarcoma in San Francisco. J Infect Dis 1989; 159: 569-72.
7. + lymphocyte counts at AIDS manifestation in Germany from 1986 to 1991. AIDS 1992; 6:413-20.
8. Weiss P, Wallace M, Olson P, Rossetti R. Changes in the mix of AIDS-defining conditions. N Engl J Med 1993; 329:1962.
9. Hoover D, Saah A, Bacellar H, et al. Clinical manifestations of AIDS in the era of Pneumocystis prophylaxis. N Engl J Med 1993; 329:1922-6.
10. 3 following antiretroviral therapy for HIV-1 [abstract no 358]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, VA: IDSA for Foundation for Retroviruses and Human Health. 1997:130.
11. Lederman M, Connick E, Landay A, et al. Partial immune reconstitution after 12 weeks of HAART (AZT, 3TC, ritonavir): preliminary results of ACTG 315 [abstract no LB13]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, VA: IDSA for Foundation for Retroviruses and Human Health, 1997:208.
12. Calabrese L, Mawhorter S, Podlipsky K, et al. Immune activation and HIV infection: relationship to treatment and viral load [abstract no 84]. In: Programs and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, VA: IDSA for Foundation for Retroviruses and Human Health, 1997:80.
13. Kelleher A, Zaunders J, Sewell W, Cooley M, Carr A, Cooper D. Increased proliferative and cytokine responses following ritonavir therapy: relative contribution of lymphocyte subsets [abstract no 536]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, VA: IDSA for Foundation for Retroviruses and Human Health, 1997:164.
14. Rothen M, Bisset L, Joller-Jemelka H, Grob P, Lüthy R, Opravil M. Lymphocyte subpopulations and function improve under treatment with indinavir despite severe immunodeficiency [abstract no 534]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, VA: IDSA for Retroviruses and Human Health, 1997:163.
15. Cossarizza A. T-cell repertoire and HIV infection: facts and perspective. AIDS 1997; 11:1075-88.
16. + T cell homeostasis and function in advanced HIV disease. Science 1997; 277:112-6.
17. British Columbia Center for Excellence in HIV/AIDS. Therapeutic guidelines for the treatment of HIV/AIDS and related conditions. Vancouver: St. Paul's Hospital, the University of British Columbia, and the Ministry of Health, British Columbia, Canada, 1996.
18. Centers for Disease Control and Prevention. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. MMWR Morb Mortal Wkly Rep 1992; 41(RR-17):1-19.
19. Neaton J, Wentworth D, Rhame F, Hogan C, Abrams D, Deyton L. Considerations in choice of a clinical end-point for AIDS clinical trials. Stat Med 1994; 13:2107-25.
20. Lundgren J, Pederson C, Clumeck N, et al. Survival differences in European patients with AIDS, 1979-1989. BMJ 1994; 308:1068-973.
21. Hogg R, O'Shaughnessy M, Gataric N, et al. Decline in deaths from AIDS due to new antiretrovirals. Lancet 1997; 349:1294.
22. Hogg RS, Heath KV, Yip B, et al. Improved survival among HIV-infected individuals following initiation of antiretroviral therapy. JAMA 1998; 279:450-4.
23. Palella F, Delaney K, Moorman A, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-60.
24. Moore R, Chaisson R. Natural history of opportunistic disease in an HIV-infected urban cohort. Ann Intern Med 1996; 127:633-42.
25. Powderly W. Multiple opportunistic infection prophylaxis. AIDS 1996; 10:S165-71.
26. Porter K, Fairley C, Wall P, et al. AIDS defining diseases in the UK: the impact of PCP prophylaxis and twelve years of change. Int J STD AIDS 1996; 7:252-7.
27. Muñoz A, Schrager L, Bacellar H, et al. Trends in the incidence of outcomes defining acquired immunodeficiency syndrome (AIDS) in the multicenter AIDS cohort study: 1985-1991. Am J Epidemiol 1993; 137:423-38.
28. Montaner J, Le T, Hogg R, et al. The changing spectrum of AIDS index diseases in Canada. AIDS 1994; 8:693-6.
29. Delmas M-C, Schwoebel V, Heisterkamp S, et al. Recent trends in Pneumocystis carinii pneumonia as AIDS-defining disease in nine European countries. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9:74-80.
30. Hirschel B, Lazzarin A, Chopard P, et al. A controlled study of inhaled pentamidine for primary prevention of Pneumocystis carinii pneumonia. N Engl J Med 1991; 324:1079-83.
31. Pradier C, Pesce A, Tailan B, Roger P, Bentz L, Dellamonica P. Reducing the incidence of Pneumocystis carinii pneumonia: a persisting challenge. AIDS 1997; 11:832-33.
32. Schwarcz S, Katz M, Hirozawa A, Gurley J, Lemp G. Prevention of Pneumocystis carinii pneumonia: who are we missing? AIDS 1997; 11: 1263-8.
33. Chang Y, Cesarman E, Pessin M, et al. Identification of new human herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994; 266:1865-9.
34. Strathdee S, Veugelers P, Moore P. The epidemiology of HIV-associated Kaposi's sarcoma: the unraveling mystery. AIDS 1996; 10(suppl A): S51-7.
35. Foreman K, Friborg J, Kong W-P, et al. Propagation of a human herpesviras from AIDS-associated Kaposi's sarcoma. N Engl J Med 1997; 336: 163-71.
36. Hermans P, Lundgren J, Sommereijns B, et al. Epidemiology of AIDS-related Kaposi's sarcoma in Europe over 10 years. AIDS 1996; 10: 911-7.
37. Dore G, Li Y, Grulich A, et al. Declining incidence and later occurrence of Kaposi's sarcoma among persons with AIDS in Australia: the Australian AIDS cohort. AIDS 1996; 10:1401-6.
38. Montaner J, Strathdee S, Veuglers P, Hogg R, Schechter M. Incidence of endobronchial Kaposi's sarcoma. Chest 1994; 106:886.
39. Jones J, Hanson D, Chu S, et al. Toxoplasmic encephalitis in HIV-infected persons: risk factors and trends. AIDS 1996; 10:1393-9.
40. Race E, Adelson-Mitty J, Barlam T, Japour A. Focal inflammatory lymphadenitis (FIL) and fever following initiation of protease inhibitor (PRI) in patients with advanced HIV-1 disease [abstract no 352]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, VA: IDSA for Foundation for Retroviruses and Human Health, 1997:129.
41. Phillips P, Zala C, Rouleau D, Montaner J. Mycobacterial lymphadenitis: can highly active antiretroviral therapy (HAART) unmask subclinical infection? [abstract no 351]. In: Program and abstracts of the 4th Conference on Retroviruses and Opportunistic Infections (Washington, DC). Alexandria, VA: IDSA for Foundation for Retroviruses and Human Health, 1997:129.
42. Jacobson M, Zegans M, Pavan P, et al. Cytomegalovirus retinitis after initiation of highly active antiretroviral therapy. Lancet 1997; 349:1443-5.
43. Health Canada. AIDS in Canada: quarterly surveillance update. Ottawa: Division of AIDS Surveillance, Bureau of HIV/AIDS and STD, LCDC, HPB, Health Canada, May 1997.